ESMO 2020 | Treatment options for mUC following chemo-immunotherapy failure

Aris Bamias, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, discusses non-chemotherapy and non-immunotherapy treatment options for heavily pre-treated patients with locally advanced or metastatic urothelial carcinoma (mUC) at the ESMO education weekend 2020. Dr Bamias highlights two agents that have recently been granted FDA approval: enfortumab vedotin and erdafitinib. Enfortumab vedotin is an antibody-drug conjugate targeting nectin-4 that has been approved based on results from the EV-201 study, which reported a response rate of over 50% (NCT03219333). Erdafitinib has been approved for patients with susceptible FGFR3 or FGFR2 genetic alterations, accounting for around 20% of patients with mUC, based on the results of the BLC2001 study (NCT03390504), which reported a response rate of around 50%. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).